Stay on Top of Changes to COVID-19 Management
February 2022
Questions are popping up about changes with COVID-19 management...monoclonal antibodies (MAbs), remdesivir, etc.
It's partly because FDA has halted use of the MAbs bamlanivimab/etesevimab and casirivimab/imdevimab (Regen-COV)...since they don't work against the current Omicron variant.
Anticipate that the oral antiviral nirmatrelvir/ritonavir (Paxlovid) will be preferred for outpatients instead.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote